Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

Rigshospitalet

Status: Completed

Conditions: Neovascular Age-related Macular Degeneration

Treatments: Drug: Faricimab

Study type: Observational

Funder types: Other

Identifiers

NCT06231121

MULTISW-VAB1SHOT

Details and patient eligibility

About

The goal of this retrospective single-center chart review is to establish the response rate, efficacy and safety of a single dose of intravitreal faricimab injection in real-world patients with aflibercept- and ranibizumab-resistant neovascular age-related macular degeneration.

Enrollment: 13 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Presence of neovascular age-related macular degeneration (AMD) in the study eye
• Previous treatment with minimum 6 consecutive, monthly aflibercept (Eylea®) injections in the study eye without optimal treatment response, defined as persisting intraretinal fluid or subretinal fluid or both on optical coherence tomography scans
• Subsequently, a sequential switch to ranibizumab (Lucentis®), with minimum 1 injection, also without optimal response
• Finally, a sequential treatment switch from ranibizumab to faricimab.

Exclusion criteria

• Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye
• Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye
• Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch

Trial design

13 participants in 1 patient group

Patients

Description:

Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.

Treatment:

Drug: Faricimab